Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
21 shown of 7,019 total abstracts
  1. Abstract 63672026-06-03 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    F. Andre, S. Tolaney, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  2. Abstract 69522026-06-02 · 15:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-425
    R. Herbst, S. Antonia, H. Borghaei, et al. · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  3. Abstract 67332026-06-05 · 20:30 CT · S100A
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-132
    J. Cortes, E. Winer, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 61972026-06-02 · 18:30 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in RCC
    C. Saura, P. Schmid, M.C. Garassino, et al. · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 61952026-06-01 · 20:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-670
    M. Reck, R. Herbst, H. Borghaei · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 66782026-06-04 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-482 study)
    L. Paz-Ares, P. Schmid, M. Krop · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  7. Abstract 61002026-06-03 · 19:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-980 study)
    S. Modi, A. Spira, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  8. Abstract 67802026-06-02 · 14:00 CT · S406
    KEYNOTE-905: Keytruda (pembrolizumab) adjuvant in RCC
    A. Spira, M. Krop · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  9. Abstract 69422026-06-03 · 15:45 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-994
    C. Robert, H. Rugo, A. Spira · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 68652026-06-01 · 19:30 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-227
    M.C. Garassino, C. Robert, T. Mok · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 65482026-06-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-762 study)
    J. Cortes, E. Winer, J. Brahmer · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  12. Abstract 66702026-06-03 · 19:15 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-841 study)
    C. Saura, M.C. Garassino, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  13. Abstract 69902026-06-01 · 16:30 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-537 study)
    C. Saura, E. Winer, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  14. Abstract 64332026-06-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-789 study)
    C. Robert, L. Paz-Ares, F. Andre, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  15. Abstract 60262026-06-04 · 13:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-475
    H. Borghaei, J. Brahmer, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  16. Abstract 62902026-06-03 · 18:30 CT · S406
    CheckMate-66: Opdivo (nivolumab) 1L in RCC
    S. Antonia, J. Brahmer, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  17. Abstract 63852026-06-05 · 19:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-721 study)
    M. Reck, C. Robert, S. Modi · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 62492026-06-04 · 21:30 CT · S100A
    KEYNOTE-352: Keytruda (pembrolizumab) 1L in RCC
    S. Peters, S. Antonia, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  19. Abstract 66022026-06-03 · 21:15 CT · E450
    KEYNOTE-668: Keytruda (pembrolizumab) 1L in RCC
    G. Curigliano, S. Peters, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  20. Abstract 66332026-06-02 · 14:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-772
    P. Schmid, H. Rugo · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  21. Abstract 64182026-06-05 · 14:30 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-534 study)
    J. Brahmer, H. Rugo · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.